Lisen Imprinting Diagnostics has been chosen by Merck as one of the healthcare startups for their 2019 Accelerator Program in China. Lisen initially bested out almost 300 other Asian technology companies to qualify among the 17 startups which were given the opportunity to attend their Accelerator workshop in Shanghai held last October 21-23,2019. Lisen topped the final selection of six innovation startups, and this award from Merck included mentoring from senior management and a global network of experts, coaching sessions and workshops by the external and the internal innovation ecosystem, attendance to events which will help connect Lisen across a range of industries and investors, and a seed funding of up to 50,000 Euros. Starting from November, Merck will work with Lisen in the China Innovation Hub to facilitate the process of partnership.
